| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2969881 | The Journal of Heart and Lung Transplantation | 2016 | 9 Pages |
Abstract
Total HLA mismatches are associated with increased risk for BOS, specifically at the A locus. Induction with alemtuzumab or basiliximab reduced the risk, whereas greater ischemic time appears to also be protective.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Don MD, MS, Sylvester M. MD, PhD, Joseph D. MD, Benjamin T. MD, Stephen E. MD, Heidi M. PhD, Bryan A. MD, PhD,